ravulizumab

Home
Ligands
ravulizumab

GtoPdb Ligand ID: 10168

Synonyms: ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®

ravulizumab is an approved drug (FDA (2018), EMA (2019))

Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.

Immunopharmacology Comments
Like 6884, ravulizumab binds to complement component C5 thus inhibiting the production of C5a and the membrane attack complex. This mechanism blocks complement-mediated hemolysis. The terminal half-life of free ravulizumab is 25~ days, and for C5-bound ravulizumab it is ~13 days [3]. The corresponding values for eculizumab are ~27 days and ~4 days for the free and C5-bound antibody.

Immunopharmacology Comments

Like 6884, ravulizumab binds to complement component C5 thus inhibiting the production of C5a and the membrane attack complex. This mechanism blocks complement-mediated hemolysis. The terminal half-life of free ravulizumab is 25~ days, and for C5-bound ravulizumab it is ~13 days [3]. The corresponding values for eculizumab are ~27 days and ~4 days for the free and C5-bound antibody.